Back
HFA Premium Access

Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy

Session: Pharmacology in heart failure - what is in horizon?
Topic: Pharmacotherapy
Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)
Event: Heart Failure 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)
62 presentations
15 followers

3 more presentations in this session

Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved

Speaker: Professor G. Filippatos (Athens, GR)

Access
Abstract
Slides
Like
Thumbnail

Intravenous infusion of the beta-3 adrenergic receptor antagonist APD418 improves left ventricular function in dogs with systolic heart failure despite long-term therapy with beta-blockers

Speaker: Professor H. Sabbah (Detroit, US)

Access
Abstract
Slides
Like
Thumbnail

Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study

Speaker: Doctor J. Larsson (Copenhagen, DK)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Pharmacology in heart failure - what is in horizon?

Speakers: Doctor P. Garcia-Pavia, Professor G. Filippatos, Professor H. Sabbah, Doctor J. Larsson
Access
Like
Thumbnail

About the event

Image

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources